Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MISSISSAUGA, Ontario & BRISBANE, Calif.--(BUSINESS WIRE)--CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML HealthCare”), a leading provider of medical diagnostic services in Canada, and XDx, Inc. (“XDx”), a leading U.S. molecular diagnostics company focused on high clinical impact blood tests for transplantation and autoimmune diseases, today entered into an exclusive licensing agreement that provides CML HealthCare with exclusive rights, initially in Ontario, to AlloMap, XDx’s flagship diagnostic blood test used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection. The agreement also provides the Company with the option to extend the distribution and marketing rights to AlloMap across Canada.
Help employers find you! Check out all the jobs and post your resume.
MISSISSAUGA, Ontario & BRISBANE, Calif.--(BUSINESS WIRE)--CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML HealthCare”), a leading provider of medical diagnostic services in Canada, and XDx, Inc. (“XDx”), a leading U.S. molecular diagnostics company focused on high clinical impact blood tests for transplantation and autoimmune diseases, today entered into an exclusive licensing agreement that provides CML HealthCare with exclusive rights, initially in Ontario, to AlloMap, XDx’s flagship diagnostic blood test used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection. The agreement also provides the Company with the option to extend the distribution and marketing rights to AlloMap across Canada.
Help employers find you! Check out all the jobs and post your resume.
